10/29
09:09 pm
shph
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
Medium
Report
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules [Yahoo! Finance]
10/29
09:05 pm
shph
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
Medium
Report
Shuttle Pharmaceuticals Holdings, Inc. Announces Pricing of $4.5 Million Public Offering Priced At-The-Market Under Nasdaq Rules
10/29
04:05 pm
shph
Shuttle Pharma Pays Off Senior Secured Convertible Note
Medium
Report
Shuttle Pharma Pays Off Senior Secured Convertible Note
10/29
09:00 am
shph
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
High
Report
Shuttle Pharma Doses First Patients in Phase 2 Clinical Trial of Ropidoxuridine for Treatment of Patients with Glioblastoma
10/28
04:05 pm
shph
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
High
Report
Shuttle Pharma Completes Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
10/28
09:00 am
shph
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
Medium
Report
Shuttle Pharmaceuticals to Present at the 2024 ThinkEquity Conference on Wednesday, October 30, 2024
9/16
09:00 am
shph
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
Low
Report
Shuttle Pharma Expands Clinical Trial Site Enrollment for Phase 2 of Ropidoxuridine for Treatment of Patients with Glioblastoma
9/5
09:00 am
shph
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
High
Report
Shuttle Pharma Announces Issuance of U.S. Patent for Selective Histone Deacetylase Inhibitors for the Treatment of Human Disease
9/4
04:15 pm
shph
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
Medium
Report
Shuttle Pharma Provides Second Quarter 2024 Corporate Update
8/28
09:00 am
shph
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
High
Report
Shuttle Pharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
8/26
04:16 pm
shph
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) [Yahoo! Finance]
Medium
Report
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1) [Yahoo! Finance]
8/26
04:10 pm
shph
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)
Medium
Report
Shuttle Pharma Receives Notice of Nasdaq Non-Compliance with Listing Rule 5250(c)(1)